Students taking Wellmune WGP stay healthier
December 14, 2010
by Jeff Gelski
EAGAN, MINN. — The number of days with reported upper respiratory tract infection was reduced significantly in a group of students taking Wellmune WGP when compared with a group taking a placebo, according to the results of a study presented in December at the British Society for Immunology conference in Liverpool, United Kingdom.
Eagan-based Biothera offers Wellmune WGP, which is derived from the cell wall of yeast (Saccharomyces cerevisiae) and used as an ingredient in foods, beverages and supplements.
The study involved researchers from the University of Southampton in Southampton, United Kingdom; The Dove Clinic; and Southampton University Hospitals. In the randomized, double-blind, placebo-controlled study, 100 medical students took either 250 mg daily of Wellmune WGP or an identical placebo capsule for 90 days. The students kept a daily health diary. The Wellmune WGP group reported upper respiratory tract infection symptoms in 198 days, which compared with 241 days for the placebo group.
“Medical students working long hours in hospitals are placing tremendous stress on their immune systems,” said Richard Fuller, M.D., of the Dove Clinic for Integrated Medicine and principal investigator for the study. “Wellmune WGP activates innate immune cells, the body’s first line of defense, which helped students become more resilient to health challenges.”